Bionote, strategically invests in Centenaire Biosciences... initiating business diversification in earnest

- Carried out 16.5 million USD capital investment in addition to the 7.8 million USD invested last year - Business diversification through joint development of therapeutic antibody    Bionote announced on the 8th of February, that they have entered into a contract with therapeutic antibody development company, Centenaire Biosciences ("Centenaire"), through which Bionote invested 16.5 million USD as capital investment.   The total investment amount amounts to 24.3 million USD, including the 7.8 million USD invested last year along with SD Investment. The total share held increased from 9.09% to 27%. Bionote plans to continue their ongoing partnership with Centenaire through this investment, especially in co-developing new therapeutic antibody pipelines.   Centenaire is a sister company of Meditox, founded in 2021. They have been developing treatments for cancer, autoimmune diseases, and nervous system diseases through their innovative antibody platform technology. CTN001, which has been shown to be greatly effective for HER2 low-expression cancer has especially great market potential as the HER2 accounts for over 50% of breast cancers.   The two companies are planning for the clinical trials of the CTN001 product, signing a contract with Samsung Biologics and developing the process for the manufacture of clinical samples. Furthermore, the two companies are also cooperating in the development of new treatments for non-small cell lung cancer and acute myeloid leukemia as well as cancer immunotherapy amongst various next generation anti-cancer treatments, expanding their research further.   Dr. Byung Ki Cho, CEO of Bionote, commented that "We will strive to develop new, revolutionary therapeutic antibodies through our unrivaled antibody, antigen technology, coupled with the R&D capabilities of our company, which will synergize with Centenaire's innovative antibody platform technology". Ki Hyeok Yang, CEO of Centenaire, also commented that they would like to "Thank Bionote for trusting in the technology and development capabilities of Centenaire, continuing to invest large amounts in both 2022 and 2023." and added that "Centenaire will grow to be a game changer in the market by continuing to develop our own, original, products through our antibody platform technology, in a market full of new innovation, such as cancer immunotherapy, antibody-drug conjugates and T-cell engagers. 

• 2023.02.08
• Hits : 4,018

Bionote Expands Into Veterinary Clinical Chemistry Market

DISCLAIMER: This news article is a direct translation of the original Korean article from Korea Business TV. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.​​Bionote, an in vitro diagnostic product manufacturer, announced on the 23rd that they will be expanding into the clinical chemisry market, which is expected to grow to 1.25 billion USD by 2026.Bionote also announced that they are in the process of applying for approval of domestic and international sale of their clinical chemistry analyzer 'Vcheck C' and that they will start the approval process by January.This new product is capable of testing up to 4 samples at once, taking only 10 minutes on average, for quantitative detection of proteins, enzymes, amylase, etc. in the patient's blood samples, in order to give the veterinarian a general idea of the health of the patient in question, without sending the samples to a lab to get tested. everything can be performed on-site using this POC Clinical Chemistry Analyzer.The Clinical Chemistry market is currently valued at 768.6 million USD, and is expected to expand up to 1.25 billion USD by 2026.Bionote's CEO, DVM Byeong-Ki Cho, stated that "Bionote will provide a total diagnostic solution in the veterinary field through our Rapid, ELISA, Fluorescent immunoassay and POC Molecular Diagnostic devices as well as our new Clinical Chemistry analyzer, further improving our position as one of the global leaders in the veterinary field"Link to original article: https://www.wowtv.co.kr/NewsCenter/News/Read?articleId=A202212230095&t=NN

• 2022.12.23
• Hits : 5,095

Bionote, Listed on KOSPI (Korea Composite Stock Price Index) as of 22nd of December

DISCLAIMER: This news article is a direct translation of the original Korean article from MTN. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.Bionote, a veterinary diagnostics and biological raw materials company, has been listed on KOSPI, the Korea Composite Stock Price Index, as of 22nd of December.At the Listing Event held at the Korea Exchange on the 22nd, DVM Byung-Ki Cho (CEO of Bionotoe), Jae-Jun Lim (Head of Korea Exchange Securities Market Division), Young-Chae Jeong (CEO of NH Investments & Securities), Il-Moon Jeong (CEO of Korea Investments & Securities) and Nam-Ki Chae (President of Korea IR Service) was in attendance.Bionote, founded in 2003, is a affiliate company of SD Biosensor and has become one of the world's leading veterinary diagnostics and biological raw materials company representing Korea, through the accumulation of proprietary R&D and know-how.Based on the company's unique genetic recombinant antigen/antibody development technical ability and manufacturing technology, it stands out in the immunodiagnostics field. Furthermore, the company can implement all processes from raw material manufacturing to finished product manufacturing through its proprietary technologies.Bionote's KOSPI listing is expected to be a giant leap towards becoming top 3 in the world in animal diagnostics and biological raw materials field. Increased brand recognition, advantageous positionings in M&A negotiations and recruitment of talented individuals are just some of the advantages of being listed on KOSPI, through which Bionote will continue to accelerate the expansion of the company and its businessEarlier, CEO of Bionote, DVM Byung-Ki Cho, strongly emphasized that he will personally make sure to fulfill Bionote's responsibilities and obligations to its investors as well as share the fruits of corporate growth with its investors.Link to original article: https://news.mtn.co.kr/news-detail/2022122208163498203 

• 2022.12.23
• Hits : 3,795